„Gentle insulinisation“: Insulin bei Typ-2-Diabetes – patientengerecht, einfach, effektiv

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Univ.-Prof. Dr. Thomas C. Wascher

1. Medizinische Abteilung, Hanusch-Krankenhaus, Wien


1 Clodi M et al., Antihyperglykämische Therapie bei Diabetes mellitus Typ 2. Wien Klin Wochenschr 2012; 124(Suppl 2):10–6

2 Inzucchi SE et al., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364–79

3 Lasserson DS et al., Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009; 52:1990–2000

4 Rodbard HW et al., Treatment intensification with step­wise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomized, treat-to-target clinical trial. Lancet Diabetes Endocrinol 2014; 2:30–7

5 Meneghini L et al., Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011; 17:727–36

6 Davidson MB et al., A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011; 17:395–403

7 Garber AJ et al., Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006; 8:58–66

8 Strojek K et al., Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009; 25:2887–94

9 Ligthelm RJ et al., Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomized open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006; 114:511–9


UIM 08|2014

Herausgeber: o. Univ.-Prof. Dr. Günter J. Krejs, Österreichische Gesellschaft für Innere Medizin
Publikationsdatum: 2014-11-20